Concepedia

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

Wolfgang Kruis, Laimas Virginijus Jonaitis, Juris Pokrotnieks, M. Horyński, M Bátovský, Y. S. Lozynsky, Yu. M. Zakharash, I Rácz, K Kull, Aleksandar Včev,

Alimentary Pharmacology & Therapeutics · 2010 · 79 citations · 14 references

DOI

Abstract

Mesalazine 3.0 g once daily was the most effective dose for maintenance of remission in ulcerative colitis of the three regimens assessed, with no penalty in terms of safety.

References

14

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Daniel Rachmilewitz · BMJ · 1989 · 1K citations · Full text

Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease

Matthew Shale, S Riley · Alimentary Pharmacology & Therapeutics · 2003 · 256 citations

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

M A Kamm, Gary R. Lichtenstein, William J. Sandborn et al. · Gut · 2008 · 175 citations · Full text

An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis

Stephen B. Hanauer · Annals of Internal Medicine · 1996 · 156 citations

Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis

Bernd Bokemeyer, Henning Adamek, Lars Vinter‐Jensen et al. · Clinical Gastroenterology and Hepatology · 2009 · 152 citations · Full text

, , +4